Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy

<p dir="ltr">Lactate dehydrogenase C (LDHC) is an archetypical cancer testis antigen with limited expression in adult tissues and re-expression in tumors. This restricted expression pattern together with the important role of LDHC in cancer metabolism renders LDHC a potential target...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Remy Thomas (702843) (author)
مؤلفون آخرون: Hibah Shaath (5599658) (author), Adviti Naik (673163) (author), Salman M. Toor (8854751) (author), Eyad Elkord (5396390) (author), Julie Decock (44558) (author)
منشور في: 2020
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513555912458240
author Remy Thomas (702843)
author2 Hibah Shaath (5599658)
Adviti Naik (673163)
Salman M. Toor (8854751)
Eyad Elkord (5396390)
Julie Decock (44558)
author2_role author
author
author
author
author
author_facet Remy Thomas (702843)
Hibah Shaath (5599658)
Adviti Naik (673163)
Salman M. Toor (8854751)
Eyad Elkord (5396390)
Julie Decock (44558)
author_role author
dc.creator.none.fl_str_mv Remy Thomas (702843)
Hibah Shaath (5599658)
Adviti Naik (673163)
Salman M. Toor (8854751)
Eyad Elkord (5396390)
Julie Decock (44558)
dc.date.none.fl_str_mv 2020-01-13T06:00:00Z
dc.identifier.none.fl_str_mv 10.1007/s00262-020-02480-4
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Identification_of_two_HLA-A_0201_immunogenic_epitopes_of_lactate_dehydrogenase_C_LDHC_potential_novel_targets_for_cancer_immunotherapy/21596949
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Clinical sciences
Immunology
Oncology and carcinogenesis
LDHC
Lactate dehydrogenase
Cancer testis antigen
Epitopes
Adoptive T cell therapy
Cancer immunotherapy
dc.title.none.fl_str_mv Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <p dir="ltr">Lactate dehydrogenase C (LDHC) is an archetypical cancer testis antigen with limited expression in adult tissues and re-expression in tumors. This restricted expression pattern together with the important role of LDHC in cancer metabolism renders LDHC a potential target for immunotherapy. This study is the first to investigate the immunogenicity of LDHC using T cells from healthy individuals. LDHC-specific T cell responses were induced by in vitro stimulation with synthetic peptides, or by priming with autologous peptide-pulsed dendritic cells. We evaluated T cell activation by IFN-γ ELISpot and determined cytolytic activity of HLA-A*0201-restricted T cells in breast cancer cell co-cultures. In vitro T cell stimulation induced IFN-γ secretion in response to numerous LDHC-derived peptides. Analysis of HLA-A*0201 responses revealed a significant T cell activation after stimulation with peptide pools 2 (PP2) and 8 (PP8). The PP2- and PP8-specific T cells displayed cytolytic activity against breast cancer cells with endogenous LDHC expression within a HLA-A*0201 context. We identified peptides LDHC<sup>41−55</sup> and LDHC<sup>288−303</sup> from PP2 and PP8 to elicit a functional cellular immune response. More specifically, we found an increase in IFN-γ secretion by CD8 + T cells and cancer-cell-killing of HLA-A*0201/LDHC positive breast cancer cells by LDHC<sup>41−55</sup>- and LDHC<sup>288−303</sup>-induced T cells, albeit with a possible antigen recognition threshold. The majority of induced T cells displayed an effector memory phenotype. To conclude, our findings support the rationale to assess LDHC as a targetable cancer testis antigen for immunotherapy, and in particular the HLA-A*0201 restricted LDHC<sup>41–5</sup>5 and LDHC288–303 peptides within LDHC.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Immunology, Immunotherapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s00262-020-02480-4" target="_blank">http://dx.doi.org/10.1007/s00262-020-02480-4</a></p>
eu_rights_str_mv openAccess
id Manara2_874a02a43cd8925f66489a393ae20a09
identifier_str_mv 10.1007/s00262-020-02480-4
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/21596949
publishDate 2020
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapyRemy Thomas (702843)Hibah Shaath (5599658)Adviti Naik (673163)Salman M. Toor (8854751)Eyad Elkord (5396390)Julie Decock (44558)Biomedical and clinical sciencesClinical sciencesImmunologyOncology and carcinogenesisLDHCLactate dehydrogenaseCancer testis antigenEpitopesAdoptive T cell therapyCancer immunotherapy<p dir="ltr">Lactate dehydrogenase C (LDHC) is an archetypical cancer testis antigen with limited expression in adult tissues and re-expression in tumors. This restricted expression pattern together with the important role of LDHC in cancer metabolism renders LDHC a potential target for immunotherapy. This study is the first to investigate the immunogenicity of LDHC using T cells from healthy individuals. LDHC-specific T cell responses were induced by in vitro stimulation with synthetic peptides, or by priming with autologous peptide-pulsed dendritic cells. We evaluated T cell activation by IFN-γ ELISpot and determined cytolytic activity of HLA-A*0201-restricted T cells in breast cancer cell co-cultures. In vitro T cell stimulation induced IFN-γ secretion in response to numerous LDHC-derived peptides. Analysis of HLA-A*0201 responses revealed a significant T cell activation after stimulation with peptide pools 2 (PP2) and 8 (PP8). The PP2- and PP8-specific T cells displayed cytolytic activity against breast cancer cells with endogenous LDHC expression within a HLA-A*0201 context. We identified peptides LDHC<sup>41−55</sup> and LDHC<sup>288−303</sup> from PP2 and PP8 to elicit a functional cellular immune response. More specifically, we found an increase in IFN-γ secretion by CD8 + T cells and cancer-cell-killing of HLA-A*0201/LDHC positive breast cancer cells by LDHC<sup>41−55</sup>- and LDHC<sup>288−303</sup>-induced T cells, albeit with a possible antigen recognition threshold. The majority of induced T cells displayed an effector memory phenotype. To conclude, our findings support the rationale to assess LDHC as a targetable cancer testis antigen for immunotherapy, and in particular the HLA-A*0201 restricted LDHC<sup>41–5</sup>5 and LDHC288–303 peptides within LDHC.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer Immunology, Immunotherapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s00262-020-02480-4" target="_blank">http://dx.doi.org/10.1007/s00262-020-02480-4</a></p>2020-01-13T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s00262-020-02480-4https://figshare.com/articles/journal_contribution/Identification_of_two_HLA-A_0201_immunogenic_epitopes_of_lactate_dehydrogenase_C_LDHC_potential_novel_targets_for_cancer_immunotherapy/21596949CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215969492020-01-13T06:00:00Z
spellingShingle Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
Remy Thomas (702843)
Biomedical and clinical sciences
Clinical sciences
Immunology
Oncology and carcinogenesis
LDHC
Lactate dehydrogenase
Cancer testis antigen
Epitopes
Adoptive T cell therapy
Cancer immunotherapy
status_str publishedVersion
title Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
title_full Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
title_fullStr Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
title_full_unstemmed Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
title_short Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
title_sort Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
topic Biomedical and clinical sciences
Clinical sciences
Immunology
Oncology and carcinogenesis
LDHC
Lactate dehydrogenase
Cancer testis antigen
Epitopes
Adoptive T cell therapy
Cancer immunotherapy